Royal Bank of Canada
FENC icon

Royal Bank of Canada’s Fennec Pharmaceuticals FENC Stock Holding History

Royal Bank of Canada’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,467
Closed -$19K – 7294
2025
Q4 		$19K Buy
2,467
+1,356
+122% +$11.1K ﹤0.01% 6077
2025
Q3 		$10K Sell
1,111
-1,864
-63% -$16.1K ﹤0.01% 6473
2025
Q2 		$25K Buy
2,975
+41
+1% +$280 ﹤0.01% 6188
2025
Q1 		$18K Sell
2,934
-1,738
-37% -$11.2K ﹤0.01% 5956
2024
Q4 		$29K Buy
4,672
+1,644
+54% +$8.42K ﹤0.01% 5947
2024
Q3 		$15K Buy
3,028
+817
+37% +$4.73K ﹤0.01% 6201
2024
Q2 		$13K Buy
2,211
+1,615
+271% +$13.4K ﹤0.01% 6238
2024
Q1 		$7K Sell
596
-6,506
-92% -$65.3K ﹤0.01% 6327
2023
Q4 		$79K Buy
7,102
+1,236
+21% +$10.2K ﹤0.01% 5752
2023
Q3 		$43K Buy
5,866
+2,684
+84% +$21.8K ﹤0.01% 5857
2023
Q2 		$28K Buy
3,182
+2,758
+650% +$22.9K ﹤0.01% 6038
2023
Q1 		$4K Buy
424
+133
+46% +$1.23K ﹤0.01% 6621
2022
Q4 		$3K Buy
291
+277
+1,979% +$2.45K ﹤0.01% 6851
2022
Q3 		$0 Sell
14
-259
-95% -$1.78K ﹤0.01% 7566
2022
Q2 		$2K Buy
273
+162
+146% +$940 ﹤0.01% 6944
2022
Q1 		$1K Buy
111
+94
+553% +$474 ﹤0.01% 7590
2021
Q4 		$0 Sell
17
-77
-82% -$573 ﹤0.01% 7734
2021
Q3 		$1K Sell
94
-319
-77% -$2.39K ﹤0.01% 7467
2021
Q2 		$3K Sell
413
-1,698
-80% -$11.3K ﹤0.01% 7178
2021
Q1 		$13K Buy
2,111
+906
+75% +$6.82K ﹤0.01% 6673
2020
Q4 		$9K Buy
1,205
+1,039
+626% +$7.91K ﹤0.01% 6419
2020
Q3 		$1K Sell
166
-325
-66% -$2.29K ﹤0.01% 6422
2020
Q2 		$4K Buy
491
+457
+1,344% +$3.4K ﹤0.01% 6096
2020
Q1 		$0 Sell
34
-43
-56% -$280 ﹤0.01% 6763
2019
Q4 		$0 Sell
77
-728
-90% -$3.91K ﹤0.01% 6903
2019
Q3 		$4K Buy
805
+507
+170% +$2.24K ﹤0.01% 6090
2019
Q2 		$1K Buy
298
+95
+47% +$402 ﹤0.01% 6693
2019
Q1 		$1K Sell
203
-298
-59% -$1.96K ﹤0.01% 6638
2018
Q4 		$3K Sell
501
-437
-47% -$3.05K ﹤0.01% 6324
2018
Q3 		$8K Buy
938
+869
+1,259% +$8.06K ﹤0.01% 6069
2018
Q2 		$1K Buy
+69
New +$818 ﹤0.01% 6350

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Royal Bank of Canada's FENC Position: Q1 2026 in Review

Royal Bank of Canada sold out of Fennec Pharmaceuticals (FENC) in Q1 2026, closing a stake of 2,467 shares — an estimated $19K sold.

Royal Bank of Canada first reported a position in FENC in Q2 2018 and held it in 31 quarters. The position peaked at $79K in Q4 2023. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Royal Bank of Canada reported no remaining Fennec Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 2,467 Fennec Pharmaceuticals shares in Q1 2026, an estimated $19K.
  • Royal Bank of Canada first reported a position in Fennec Pharmaceuticals in Q2 2018 and held it in 31 quarters.
  • Royal Bank of Canada's Fennec Pharmaceuticals position peaked at $79K in Q4 2023.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.